Table 3. Secondary outcomes.
| Outcomes | All studies | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| n | References | Proportion of events (%) | Random effect model | Fixed effects model | Homogeneity | ||||
| RR | 95% CI (p value) | RR | 95% CI (p value) | P value | I2 (%) | ||||
| Patient centered secondary outcomes | |||||||||
| All-cause mortality | 22 | [11, 12, 15, 16, 21, 23–39] | (T) 357/3356 (10.6) (P) 289/2080(13.9) Total: 646/5436(11.9) |
1.09 | 0.92–1.29 (p = 0.32) |
1.07 |
0.93–1.23 (p = 0.34) |
0.39 | 6 |
| Cardiac mortality | 20 | [11, 12, 15, 16, 23–38] | (T) 20/1022 (2.0) (P) 12/587 (2.0) Total: 32/1609 (2.0) |
0.86 | 0.41–1.80 (p = 0.69) | 0.89 | 0.45–1.75 (p = 0.73) |
0.65 | 0 |
| All-cause hospitalization | 10 | [11, 12, 15, 23, 25, 27, 28, 31–33, 38] | (T) 180/1362 (13.2) (P) 86/538 (16.0) Total: 266/1900(14.0) |
0.85 | 0.64–1.12 (p = 0.25) | 0.85 | 0.66–1.10 (p = 18) |
0.38 | 7 |
| Cardiac Hospitalization | 13 | [11, 12, 15, 16, 21, 23, 25, 27, 28, 31, 33, 37, 38] | (T) 366/2289 (16) (P) 242/1407 (17.2) Total: 608/3696(16.5) |
0.97 | 0.74–1.27 (p = 0.81) | 1.01 | 0.87–1.18 (= 0.88) |
0.08 | 41 |
| Treatment discontinuation | 22 | [11, 12, 15, 16, 21, 23–39] | (T) 544/3120 (17.4) (P) 270/1848 (14.6) Total: 814/4968 (16.4) |
1.31 | 1.15–1.50 (p<0.001) | 1.34 | 1.17–1.54 (p<0.001) |
0.84 | 0 |
| Hemodynamic outcomes | |||||||||
| Outcomes | n | References | Random effect model | Fixed effects model | Homogeneity | ||||
| MD | 95% CI (p value) | MD | 95% CI (p value) | P value | I2 (%) | ||||
| sPAP | 7 | [11, 24, 25, 29, 31–33] | N/A | -7.5 | -14.9, -0.1 (p = 0.05) |
-12.4 |
-13.5, -11.3 (p<0.001) | <0.001 | 97 |
| NT-proBNP | 10 | [12, 25, 27, 31–34, 37–39] | N/A | -240 | -578, -98 (p = 0.16) |
-214 |
-324, -104 (p<0.001) | <0.001 | 78 |